Evidence map›Paper›PMID 41244006›Full record

ReviewMedComm2025

Protein Kinase C Family: Structures, Biological Functions, Diseases, and Pharmaceutical Interventions.

Yongqi Li, Yuhan Jiang, Zhengxi Hu, Shenglan Yang, Longyin Li, Chaohu Xiong, Ya Gao, Weiguang Sun, Yonghui Zhang

Abstract readReview
In one paragraph

Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yongqi LiHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Yuhan JiangHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Zhengxi HuHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Shenglan YangHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Longyin LiHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Chaohu XiongHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Ya GaoKey Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China; State Key Laboratory of Esophageal Cancer Prevention & Treatment; Key Laboratory of Henan Province For Drug Quality and Evaluation; Institute of Drug Discovery and Development; School of Pharmaceutical Sciences, Zhengzhou University Zhengzhou China.
Weiguang SunHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Yonghui ZhangHubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein kinase C (PKC) family represents pivotal regulators in cellular signaling, whose dysregulation has been implicated in diverse human diseases, including cancer, neurodegenerative disorders, and metabolic syndromes. PKCs transduce extracellular signals through lipid-mediated activation and controlled subcellular translocation. Their activity is orchestrated by a multistep life cycle, encompassing constitutive phosphorylation during maturation, second messenger-dependent activation, and agonist-driven termination. Despite extensive investigation, critical gaps remain in the isoform-specific signaling networks and the structural determinants that underlie PKC functional diversity, thereby limiting the development of targeted therapies. In this review, we provide a comprehensive analysis of the PKC family, covering isoform diversity, structural and functional attributes, physiological roles, involvement in disease pathogenesis, therapeutic targeting strategies, as well as current controversies and research challenges. PKCs precisely regulate cell fate through subtype-specific signaling networks, and their structural plasticity presents unique opportunities for therapeutic intervention. By integrating recent advances from structural biology, disease models, and clinical trials, this review proposes a unified framework of PKC regulation that bridges fundamental biology with translational innovation. Ultimately, it serves as a valuable resource for elucidating the multifaceted roles of PKCs in health and disease, while providing a conceptual basis for the rational design of next-generation therapeutics.

Indexed as

autoimmune pathologiescancerphosphorylationprotein kinase C familyprotein kinase C isoformstherapeutic targets

Identifiers

PMID41244006
PMCPMC12617277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.